OncoSec Medical (OTC: ONCS today announced positive interim data from its ongoing Phase 2
trial of OMS-I100 in the treatment of metastatic melanoma. The results
were presented by principal investigator Adil Daud, MD, at the Advances
in Cancer Immunotherapy meeting at the University of California San
Francisco.
Data from the multicenter, open-label, single-arm study confirm the
safety of OncoSec's lead product candidate, ImmunoPulse, which leverages
the company's OMS electroporation technology to deliver the anti-tumor
agent pIL-12 directly into the tumor. In Phase 1 and Phase 2 studies, a
total of 47 melanoma patients have been treated to date without a single
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in